Oruka Therapeutics (ORKA) Free Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.24% |
| Dec 31, 2025 | -49.78% |
| Sep 30, 2025 | -61.06% |
| Jun 30, 2025 | -85.84% |
| Mar 31, 2025 | -65.36% |
| Dec 31, 2024 | -74.62% |
| Sep 30, 2024 | -99.20% |
| Jun 30, 2024 | -56.11% |
| Mar 31, 2024 | 36.01% |
| Dec 31, 2023 | 4.69% |
| Sep 30, 2023 | -1.11% |
| Jun 30, 2023 | 20.99% |
| Mar 31, 2023 | 12.29% |
| Dec 31, 2022 | 18.66% |
| Sep 30, 2022 | 8.87% |
| Jun 30, 2022 | 11.96% |
| Mar 31, 2022 | 0.20% |
| Dec 31, 2021 | -5.19% |
| Sep 30, 2021 | -5.53% |
| Jun 30, 2021 | -1.10% |
| Mar 31, 2021 | -6.12% |
| Dec 31, 2020 | -2.78% |
| Sep 30, 2020 | 3.59% |
| Jun 30, 2020 | 15.35% |
| Mar 31, 2020 | 11.52% |
| Dec 31, 2019 | 9.33% |
| Sep 30, 2019 | 15.65% |
| Jun 30, 2019 | 7.56% |
| Mar 31, 2019 | 15.74% |
| Dec 31, 2018 | 6.47% |
| Sep 30, 2018 | 1.31% |
| Jun 30, 2018 | -18.03% |
| Mar 31, 2018 | -31.78% |
| Dec 31, 2017 | -44.34% |
| Sep 30, 2017 | -38.67% |
| Jun 30, 2017 | -38.38% |
| Mar 31, 2017 | -21.27% |
| Dec 31, 2016 | -25.12% |
| Sep 30, 2016 | -17.43% |
| Jun 30, 2016 | -10.85% |
| Mar 31, 2016 | -14.88% |
| Dec 31, 2015 | -18.04% |
| Sep 30, 2015 | -3.62% |